Advancing the World of Health

Explore a variety of tools for your multicolor flow cytometry, from panel design to selection tools—an array of aids to support your research. These subtle changes would not have been discovered without the use of a powerful, highly sensitive technique such as the BD Rhapsody™ single-cell platform. It allowed us to study gene expression from immune populations of frozen PBMCs from people living with HIV after a nutritional intervention. Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news. Backed by cutting-edge technology and more than 50 years of flow cytometry expertise

BD FACSDiscover™ S8 Cell Sorter

BD can help you identify potential “at-risk” patients, empower clinical intervention, and advance health system insights A unique ecosystem to collaborate on flow cytometry panel design, improve cytometer efficiency and manage your laboratory. An interactive tool containing key cell information to help plan your flow cytometry experiments. The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research. Food and Drug Administration and worldwide health agencies to coordinate recall activities.

Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™. Surgical efficiency, patient safety and outcomes, procedural cost management Use a variety of training courses for instruments and applications to take full advantage of the capabilities of BD products. Explore our webinar series spanning a broad range of topics and in-depth reviews by senior scientists, professionals and clinicians. Houses many of our pre-designed multicolor flow cytometry panels.

• The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients.
• In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems.
• The lawsuit touched off a series of legal conflicts between the companies.

Medical Science Liaison jobs

The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. Quality of care, cost efficiency, healthcare worker and patient safety and experience Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.

BD Horizon RealBlue™ 705 Reagents

The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in chicken road app question, and revealed sterile particulates in 0.013 percent of the products. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations. Embecta Corporation is a standalone public company focused on diabetes care.

BD can help you optimize clinical effectiveness to help drive improvement in patient outcomes Quality standards, cost controls and efficiency

In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years. BD announced that it notified customers about the recall by letter and has been working with the U.S. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device.

Designed and validated for use with cell suspensions, whole blood and tissue pieces. BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency. In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.